|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCM9 |
Gene summary for MCM9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCM9 | Gene ID | 254394 |
| Gene name | minichromosome maintenance 9 homologous recombination repair factor | |
| Gene Alias | C6orf61 | |
| Cytomap | 6q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NXL9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 254394 | MCM9 | CCI_1 | Human | Cervix | CC | 2.67e-04 | 5.28e-01 | 0.528 |
| 254394 | MCM9 | CCI_2 | Human | Cervix | CC | 2.95e-05 | 5.65e-01 | 0.5249 |
| 254394 | MCM9 | CCI_3 | Human | Cervix | CC | 9.75e-04 | 4.66e-01 | 0.516 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
| GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCM9 | SNV | Missense_Mutation | novel | c.2618N>A | p.Pro873His | p.P873H | Q9NXL9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.914) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| MCM9 | insertion | In_Frame_Ins | novel | c.152_153insTGG | p.Asn51_Met52insGly | p.N51_M52insG | Q9NXL9 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MCM9 | insertion | Nonsense_Mutation | novel | c.150_151insTAGGATATGAACGAAAAGTGTGTCTCCCTT | p.Thr50_Asn51insTer | p.T50_N51ins* | Q9NXL9 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MCM9 | deletion | Frame_Shift_Del | novel | c.979delN | p.Val327CysfsTer48 | p.V327Cfs*48 | Q9NXL9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MCM9 | SNV | Missense_Mutation | novel | c.2281G>A | p.Val761Met | p.V761M | Q9NXL9 | protein_coding | tolerated_low_confidence(0.09) | benign(0.054) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MCM9 | SNV | Missense_Mutation | rs757245577 | c.1939N>A | p.Glu647Lys | p.E647K | Q9NXL9 | protein_coding | tolerated(0.71) | possibly_damaging(0.767) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| MCM9 | SNV | Missense_Mutation | c.2965N>A | p.Glu989Lys | p.E989K | Q9NXL9 | protein_coding | tolerated_low_confidence(0.99) | benign(0.003) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MCM9 | SNV | Missense_Mutation | c.3383N>G | p.Asp1128Gly | p.D1128G | Q9NXL9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.976) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MCM9 | SNV | Missense_Mutation | rs368955125 | c.865N>A | p.Glu289Lys | p.E289K | Q9NXL9 | protein_coding | tolerated(0.13) | benign(0.115) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MCM9 | SNV | Missense_Mutation | c.524N>C | p.Leu175Ser | p.L175S | Q9NXL9 | protein_coding | tolerated(0.72) | benign(0.035) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |